Status:
ACTIVE_NOT_RECRUITING
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response
Lead Sponsor:
Hôpital Universitaire Fattouma Bourguiba
Conditions:
Coronary Disease
Eligibility:
All Genders
20+ years
Brief Summary
The pathogenesis of CHD remains poorly known despite much research over the last few decades. Numerous non-genetic variables have been demonstrated to have a significant impact on the risk of CHD. How...
Detailed Description
The pathological basis of CHD is atherosclerosis and its clinical manifestations such as ischemia. The formation of functional collateral circulation around obstructed arteries in ischemic myocardial ...
Eligibility Criteria
Inclusion
- Patient \>20 years old
- Established coronary disease
Exclusion
- Severe hepatic dysfunction
- Disease or active pathological bleeding (e.g., gastrointestinal (GI) bleeding)
- Use of glycoprotein IIb/IIIa inhibitors or cilostazol
- inability to give informed consent.
Key Trial Info
Start Date :
August 12 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT03373552
Start Date
August 12 2015
End Date
December 31 2029
Last Update
February 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fattouma Bourguiba Hospital
Monastir, Monastir Governorate, Tunisia, 5000